CA2564751A1 - Neuropeptide receptor modulators - Google Patents

Neuropeptide receptor modulators Download PDF

Info

Publication number
CA2564751A1
CA2564751A1 CA002564751A CA2564751A CA2564751A1 CA 2564751 A1 CA2564751 A1 CA 2564751A1 CA 002564751 A CA002564751 A CA 002564751A CA 2564751 A CA2564751 A CA 2564751A CA 2564751 A1 CA2564751 A1 CA 2564751A1
Authority
CA
Canada
Prior art keywords
compound
alkyl
aryl
group
heteroarylalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002564751A
Other languages
English (en)
French (fr)
Inventor
Zhaoning Zhu
Zhong-Yue Sun
Yuanzan Ye
Deborra E. Mullins
Brian Mckittrick
Andrew Stamford
William J. Greenlee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2564751A1 publication Critical patent/CA2564751A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002564751A 2004-04-30 2005-04-28 Neuropeptide receptor modulators Abandoned CA2564751A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56684504P 2004-04-30 2004-04-30
US60/566,845 2004-04-30
PCT/US2005/014518 WO2005111031A2 (en) 2004-04-30 2005-04-28 Neuropeptide receptor modulators

Publications (1)

Publication Number Publication Date
CA2564751A1 true CA2564751A1 (en) 2005-11-24

Family

ID=35124538

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002564751A Abandoned CA2564751A1 (en) 2004-04-30 2005-04-28 Neuropeptide receptor modulators

Country Status (7)

Country Link
US (1) US7459450B2 (enExample)
EP (1) EP1747218A2 (enExample)
JP (1) JP2007535549A (enExample)
CN (1) CN1972937A (enExample)
CA (1) CA2564751A1 (enExample)
MX (1) MXPA06012504A (enExample)
WO (1) WO2005111031A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080034436A (ko) * 2005-07-21 2008-04-21 베타게논 에이비 암 치료에 사용되는 티아졸 유도체 및 유사체
WO2007049532A1 (ja) * 2005-10-25 2007-05-03 Shionogi & Co., Ltd. アミノジヒドロチアジン誘導体
EP2151435A4 (en) 2007-04-24 2011-09-14 Shionogi & Co PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
RU2476430C2 (ru) 2007-04-24 2013-02-27 Сионоги Энд Ко., Лтд. Производные аминодигидротиазина, замещенные циклической группой
BRPI0915500A2 (pt) 2008-06-13 2019-08-27 Shionogi & Co derivado heterocíclico contendo enxofre tendo atividade inibitória de beta secretase
EP2360155A4 (en) 2008-10-22 2012-06-20 Shionogi & Co 2-AMINOPYRIDIN-4-ON AND 2-AMINOPYRIDINE DERIVATIVE WITH BACE1-HEMDERING EFFECT
WO2010086613A1 (en) 2009-01-30 2010-08-05 Betagenon Ab Compounds useful as inhibitors as ampk
BR112012013854A2 (pt) 2009-12-11 2019-09-24 Shionogi & Co derivados de oxazina.
WO2012057247A1 (ja) 2010-10-29 2012-05-03 塩野義製薬株式会社 縮合アミノジヒドロピリミジン誘導体
CA2816285A1 (en) 2010-10-29 2012-05-03 Shionogi & Co., Ltd. Naphthyridine derivative
EP2703399A4 (en) 2011-04-26 2014-10-15 Shionogi & Co OXAZINE DERIVATIVE AND BACE-1 HEMMER THEREOF
EP2869897A4 (en) 2012-07-06 2016-09-28 Univ Duke ACTIVATION OF THE TRPV4 ION CHANNEL BY PHYSICAL STIMULI AND IMPORTANT ROLE FOR TRPV4 IN ORGANIC INFLAMMATION AND JUCKREIZ
US9540359B2 (en) 2012-10-24 2017-01-10 Shionogi & Co., Ltd. Dihydrooxazine or oxazepine derivatives having BACE1 inhibitory activity
WO2014127881A1 (de) 2013-02-25 2014-08-28 Merck Patent Gmbh 2-amino-3,4-dihydrc-chinazolin derivate und ihre verwendung als cathepsin d inhibitoren
WO2016028325A1 (en) * 2014-08-22 2016-02-25 Duke University Trpa1 and trpv4 inhibitors and methods of using the same for organ-specific inflammation and itch
WO2016043260A1 (ja) * 2014-09-19 2016-03-24 塩野義製薬株式会社 環状グアニジンまたはアミジン化合物
US11229628B2 (en) 2015-01-09 2022-01-25 Duke University TRPA1 and TRPV4 inhibitors and methods of using the same for organ-specific inflammation and itch
EP3439656A4 (en) 2016-04-07 2020-03-11 Duke University DOUBLE SMALL MOLECULE INHIBITORS OF TRPV4 AND TRPA1 FOR DISINFECTION AND ANESTHESIA
WO2020113077A1 (en) 2018-11-29 2020-06-04 The Research Foundation For The State University Of New York Compositions and methods for modular control of bioorthogonal ligation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO252896A0 (en) * 1996-09-24 1996-10-17 Fujisawa Pharmaceutical Co., Ltd. Amidine derivatives
GB9825652D0 (en) * 1998-11-23 1999-01-13 Celltech Therapeutics Ltd Chemical compounds
US7129242B2 (en) * 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
WO2003009848A1 (en) * 2001-07-20 2003-02-06 Pfizer Products Inc. Use of nk-1 receptor antagonists to modify unwanted behavior in dogs, cats and horses
CA2528438A1 (en) * 2003-06-03 2005-01-06 Novartis Ag P-38 inhibitors

Also Published As

Publication number Publication date
JP2007535549A (ja) 2007-12-06
WO2005111031A2 (en) 2005-11-24
WO2005111031A3 (en) 2005-12-22
US20060089351A1 (en) 2006-04-27
MXPA06012504A (es) 2006-12-15
EP1747218A2 (en) 2007-01-31
US7459450B2 (en) 2008-12-02
CN1972937A (zh) 2007-05-30

Similar Documents

Publication Publication Date Title
CA2564751A1 (en) Neuropeptide receptor modulators
US6664273B2 (en) Piperidine based MCH antagonists for treatment of obesity and CNS disorders
US6667319B2 (en) Neuropeptide Y Y5 receptor antagonists
ES2308206T3 (es) N-arilsulfonilpiperidinas con fuentes como inhibidores de gamma-secretasa.
US7157472B2 (en) Neuropeptide Y Y5 receptor antagonists
ZA200306609B (en) MCH antagonists and their use in the treatment of obesity.
JP2011006469A (ja) 肥満および関連障害の処置のための選択的メラニン濃縮ホルモンレセプターアンタゴニストとしての二環式化合物
NZ552059A (en) Piperidine derivatives as NK1 antagonists
US7109207B2 (en) Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity
EP1660478A1 (en) 2-substituted benzimidazole derivatives as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders
JP2015522021A (ja) スルホンアミド誘導体および薬物の薬物動態を向上させるためのその使用方法
US7498441B2 (en) Biaryltetrahydroisoquinoline piperidines as selective MCH receptor antagonists for the treatment of obesity and related disorders
US7361769B2 (en) Heterocyclyls as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders
HK1097263B (en) Fused ring nk1 antagonists
HK1097263A1 (en) Fused ring nk1 antagonists
HK1071567B (en) Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued